Cefiderocol in the Treatment of Multidrug-resistant Gram-negative Bacilli Infections, a Retrospective Study

Recruiting

• Conditions: Multidrug Resistant Bacterial Infection

• Registration Number: NCT05544682
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

Cefiderocol is a new antibiotic from the siderophore cephalosporin family for which there are few real-life data on its use in the treatment of infections with multidrug-resistant Gram-negative bacilli.

The circulation of bacterial strains multi-resistant to antibiotics is important at the Strasbourg University Hospital, so the investigators wish to report their local experience of the 1st uses of Cefiderocol in the treatment of infections with multi-resistant Gram-negative bacilli to antibiotics in order to better clarify the use of this antibiotic (therapeutic indication, method of administration)

Detailed Description

Not available

Study Timeline

• Study Start: 2022-09-01
• Study First Submitted: 2022-09-13
• Study First Submitted QC: 2022-09-13
• Study First Posted: 2022-09-16
• Status Verified: 2023-12
• Primary Completion: 2023-12
• Study Completion: 2023-12
• Last Update Submitted: 2023-12-12
• Last Update Posted: 2023-12-19

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Retrospective evaluation of the therapeutic management of patients treated as part of routine care with Cefiderocol	30 days post treatment with Céfiderocol	Survival, significant clinical improvement, absence of microbiological failure or infectious recurrence on day 30 after treatment with Céfiderocol

Trial Locations

Locations (1)

Service des maladies infectieuses et tropicales - CHU de Strasbourg - France; 🇫🇷 Strasbourg, France